Efficacy and safety of remiazolam besylate combined with alfentanil in bronchoscopy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070361

Enrollment

Unknown

Registered

2023-04-10

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Group BA:Remazolam-Alfentanil

Group DA:Dexmedetomidine-alfentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 45 to 65 years old; American Society of Anesthesiologists (ASA) I-II level; Operation time = 30 minutes; Pulse oxygen saturation (SpO2)>90% when inhaling air into the room

Exclusion criteria

Exclusion criteria: Known allergy history to local anesthetics (remidazolam benzenesulfonate, midazolam alfentanil, propofol); Previous lung diseases (such as COPD, respiratory failure, and asthma); Severe sleep apnea syndrome (apnea hypopnea index>40); Body mass index (BMI)>30 kg/m2; Communication barriers; Have a history of neuropsychiatric disorders, cerebrovascular diseases, or liver and kidney dysfunction; History of nasopharyngeal surgery; Second or third degree atrioventricular block; Bradycardia (Heart rate (HR)<60 beats per minute); Tobacco and alcohol dependence; Participate in other clinical trials within 3 months.

Design outcomes

Primary

Measure	Time frame
Operation completion success rate;	—

Secondary

Measure	Time frame
General information of patients;Perioperative hemodynamics;Perioperative hemodynamics;Patient intraoperative information;Satisfaction;Adverse reactions;	—

Countries

China

Contacts

Public ContactChunguang Ren

Liaocheng People's Hospital

weiyichunguang@163.com+86 13561239696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026